'Kras mutation' diaporamas de présentation

Corey J. Langer MD, FACP Director of Thoracic Oncology Abramson Cancer Center

KRAS in Non-Small Cell Lung Cancer (NSCLC) Is it Prognostic or Predictive? Is it an Actionable Target?. Corey J. Langer MD, FACP Director of Thoracic Oncology Abramson Cancer Center Professor of Medicine University of Pennsylvania Philadelphia, PA 19104. Langer Disclosures: Past 5 yrs.

694 views • 69 slides

641 views • 50 slides

LS174T

Fig. S1. B. A. GLC82. H1299. Calu3. A549. H460. EGFR. p-EGFR. MEK 1/2. p-MEK 1/2. AKT. pAKT. RAS-Act. RAS-T. actina. LS174T. SW620. HCT116. HCT15. SW480. GEO. EGFR. p-EGFR. MEK 1/2. p-MEK 1/2. AKT. pAKT. RAS-Act. RAS-T. actina.

316 views • 12 slides

Raymond N. DuBois, M.D., Ph.D. Executive Director

Biomarkers for Colorectal Cancer. The National Biomarker Development Alliance Forum March 25, 2013. Raymond N. DuBois, M.D., Ph.D. Executive Director. The Problem.

263 views • 6 slides

Background

No. of sample. KRAS WT. KRAS MT. KRAS WT. KRAS WT. KRAS WT. KRAS WT. KRAS MT (G13D). KRAS MT (G13D). KRAS MT (G13D). KRAS MT (G13D). KRAS MT (others). KRAS MT (others). KRAS MT (others). KRAS MT (others). n. %. 95%CI. n. %. 95%CI. All. 5,732. 3,577. 62.4.

134 views • 2 slides

Fritz et al, Supplementary FIGURE 2, KRAS mutation , IPMC cell culture

Fritz et al, Supplementary FIGURE 2, KRAS mutation , IPMC cell culture. A. B. Control (GGT=wt). IPMC (GTT/GGT).

117 views • 1 slides

To clarify the clinicopathological features between KRAS codon 12 and 13 mutant CRC .

KRAS WT. KRAS WT. KRAS WT. KRAS WT. KRAS MT(p.G13D). KRAS MT(p.G13D). KRAS MT(p.G13D). KRAS MT(p.G13D). KRAS MT(others). KRAS MT(others). KRAS MT(others). KRAS MT(others). P=0.5285*. P=0.0002*. P=0.0001*. 69.5%. 7.5%. 23.0%. 6.4 %. 64.5%. 29.1%. 63.4%. 7.2%.

145 views • 1 slides

EGFR Mutation

S-Table 1. Tang et al., BJC. NSCLC Cell Lines. SW900. H2122. H1975. H1437. H1838. H441. H520. H596. H661. H226. A549. EGFR Mutation. KRAS Mutation. Erlotinib Sensitivity. Histology. Gender.

591 views • 1 slides